| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 13 | 2025 | 291 | 2.320 |
Why?
|
| Fibrinolytic Agents | 12 | 2018 | 204 | 1.860 |
Why?
|
| Transcatheter Aortic Valve Replacement | 10 | 2025 | 206 | 1.790 |
Why?
|
| Myocardial Infarction | 23 | 2020 | 1097 | 1.570 |
Why?
|
| Aortic Valve Stenosis | 10 | 2025 | 346 | 1.420 |
Why?
|
| Angioplasty, Balloon, Coronary | 14 | 2011 | 184 | 1.370 |
Why?
|
| Emergency Medical Services | 9 | 2020 | 415 | 1.350 |
Why?
|
| Thrombolytic Therapy | 10 | 2018 | 209 | 1.230 |
Why?
|
| Coronary Artery Disease | 6 | 2023 | 883 | 1.120 |
Why?
|
| Acute Coronary Syndrome | 4 | 2025 | 234 | 1.010 |
Why?
|
| Embolism | 2 | 2018 | 48 | 0.990 |
Why?
|
| Coronary Occlusion | 2 | 2018 | 29 | 0.990 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2024 | 120 | 0.950 |
Why?
|
| Subclavian Steal Syndrome | 1 | 2023 | 8 | 0.850 |
Why?
|
| Cardiology | 6 | 2023 | 520 | 0.770 |
Why?
|
| Aortic Valve | 8 | 2025 | 457 | 0.750 |
Why?
|
| Coronary Angiography | 15 | 2024 | 482 | 0.740 |
Why?
|
| Coronary Artery Bypass | 6 | 2023 | 531 | 0.710 |
Why?
|
| Lipectomy | 1 | 2018 | 9 | 0.590 |
Why?
|
| Embolism, Fat | 1 | 2018 | 6 | 0.590 |
Why?
|
| Denervation | 1 | 2017 | 28 | 0.560 |
Why?
|
| Treatment Outcome | 34 | 2025 | 13011 | 0.530 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2023 | 1159 | 0.530 |
Why?
|
| Myocardial Reperfusion | 3 | 2011 | 74 | 0.500 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 559 | 0.480 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2020 | 381 | 0.480 |
Why?
|
| Angina Pectoris | 5 | 2021 | 65 | 0.470 |
Why?
|
| Stents | 10 | 2024 | 877 | 0.470 |
Why?
|
| Humans | 82 | 2025 | 133931 | 0.440 |
Why?
|
| Ventricular Function, Left | 3 | 2014 | 544 | 0.430 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2015 | 155 | 0.430 |
Why?
|
| Angioplasty, Balloon | 3 | 2011 | 162 | 0.420 |
Why?
|
| Pharmaceutical Preparations | 1 | 2013 | 92 | 0.400 |
Why?
|
| Endocarditis, Bacterial | 1 | 2014 | 137 | 0.390 |
Why?
|
| Foramen Ovale, Patent | 2 | 2022 | 19 | 0.390 |
Why?
|
| Coronary Vessels | 9 | 2023 | 566 | 0.380 |
Why?
|
| Septal Occluder Device | 2 | 2022 | 45 | 0.380 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2018 | 283 | 0.370 |
Why?
|
| Recovery of Function | 1 | 2014 | 474 | 0.370 |
Why?
|
| Myocardial Ischemia | 3 | 2011 | 364 | 0.360 |
Why?
|
| Electrocardiography | 5 | 2020 | 1006 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 452 | 0.340 |
Why?
|
| Kidney | 1 | 2017 | 1410 | 0.340 |
Why?
|
| Cardiac Catheterization | 8 | 2022 | 662 | 0.310 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 573 | 0.300 |
Why?
|
| Hospital Mortality | 5 | 2020 | 1087 | 0.300 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2021 | 54 | 0.290 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 70 | 0.290 |
Why?
|
| Critical Care | 1 | 2013 | 693 | 0.280 |
Why?
|
| Stroke | 4 | 2022 | 1073 | 0.280 |
Why?
|
| Aged | 25 | 2023 | 21730 | 0.270 |
Why?
|
| Chest Pain | 2 | 2023 | 133 | 0.260 |
Why?
|
| Heart Failure | 4 | 2022 | 2417 | 0.260 |
Why?
|
| Risk Factors | 17 | 2025 | 11086 | 0.240 |
Why?
|
| United States | 17 | 2023 | 11683 | 0.240 |
Why?
|
| Ultrasonography, Interventional | 2 | 2024 | 205 | 0.240 |
Why?
|
| Peripheral Arterial Disease | 2 | 2021 | 311 | 0.230 |
Why?
|
| Angina, Unstable | 4 | 2006 | 55 | 0.220 |
Why?
|
| Veterans | 3 | 2021 | 1761 | 0.220 |
Why?
|
| Coronary Stenosis | 2 | 2021 | 82 | 0.220 |
Why?
|
| Hemodynamics | 3 | 2022 | 868 | 0.210 |
Why?
|
| Theft | 1 | 2023 | 5 | 0.210 |
Why?
|
| Coronary Disease | 5 | 2016 | 721 | 0.210 |
Why?
|
| Hospitals, Low-Volume | 2 | 2021 | 33 | 0.210 |
Why?
|
| Subclavian Artery | 1 | 2023 | 73 | 0.200 |
Why?
|
| Coronary Restenosis | 3 | 2009 | 25 | 0.200 |
Why?
|
| Atrial Flutter | 1 | 2022 | 34 | 0.200 |
Why?
|
| Female | 33 | 2020 | 71658 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 4 | 2020 | 1334 | 0.190 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 514 | 0.190 |
Why?
|
| Reoperation | 3 | 2020 | 867 | 0.190 |
Why?
|
| Risk Assessment | 7 | 2025 | 3695 | 0.190 |
Why?
|
| Embolization, Therapeutic | 3 | 2016 | 224 | 0.190 |
Why?
|
| Triage | 2 | 2020 | 149 | 0.190 |
Why?
|
| Hemostasis, Surgical | 1 | 2001 | 36 | 0.180 |
Why?
|
| Myocardium | 1 | 2007 | 1046 | 0.180 |
Why?
|
| Atherectomy, Coronary | 2 | 2020 | 10 | 0.180 |
Why?
|
| Coronary Circulation | 4 | 2008 | 219 | 0.180 |
Why?
|
| Hypothermia | 1 | 2021 | 61 | 0.180 |
Why?
|
| Benchmarking | 1 | 2022 | 149 | 0.180 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2022 | 52 | 0.180 |
Why?
|
| Ischemia | 2 | 2021 | 383 | 0.170 |
Why?
|
| Male | 34 | 2020 | 65881 | 0.170 |
Why?
|
| Societies, Medical | 5 | 2023 | 777 | 0.170 |
Why?
|
| Hypothermia, Induced | 1 | 2021 | 170 | 0.170 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2021 | 97 | 0.170 |
Why?
|
| Pericarditis | 1 | 2020 | 43 | 0.170 |
Why?
|
| American Heart Association | 4 | 2023 | 328 | 0.170 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 17 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2020 | 38 | 0.160 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 55 | 0.160 |
Why?
|
| Time Factors | 10 | 2021 | 6588 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 88 | 0.160 |
Why?
|
| Inpatients | 2 | 2020 | 535 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2020 | 522 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 764 | 0.150 |
Why?
|
| Giardiasis | 1 | 1998 | 10 | 0.150 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 203 | 0.150 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 211 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 1201 | 0.150 |
Why?
|
| Education, Medical, Continuing | 1 | 2019 | 145 | 0.150 |
Why?
|
| Clinical Competence | 5 | 2023 | 1066 | 0.150 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2020 | 174 | 0.140 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 1489 | 0.140 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 47 | 0.140 |
Why?
|
| Middle Aged | 25 | 2020 | 29394 | 0.140 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 331 | 0.140 |
Why?
|
| Quality Improvement | 2 | 2020 | 690 | 0.140 |
Why?
|
| Body Weight | 1 | 2001 | 1034 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2018 | 395 | 0.130 |
Why?
|
| Hypertension | 3 | 2017 | 1391 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2018 | 353 | 0.130 |
Why?
|
| Echocardiography | 3 | 2019 | 1124 | 0.130 |
Why?
|
| Heart Valve Diseases | 1 | 2018 | 181 | 0.130 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 2 | 2006 | 8 | 0.130 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 478 | 0.130 |
Why?
|
| Atrial Pressure | 1 | 2016 | 6 | 0.130 |
Why?
|
| Balloon Valvuloplasty | 1 | 2016 | 25 | 0.130 |
Why?
|
| Heart Septum | 1 | 2016 | 55 | 0.130 |
Why?
|
| Diarrhea | 1 | 1998 | 341 | 0.130 |
Why?
|
| Fever | 1 | 1998 | 309 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 1998 | 298 | 0.120 |
Why?
|
| Pandemics | 2 | 2020 | 1196 | 0.120 |
Why?
|
| Health Services Accessibility | 2 | 2011 | 648 | 0.120 |
Why?
|
| Cerebrovascular Disorders | 1 | 2016 | 125 | 0.120 |
Why?
|
| Heart Transplantation | 2 | 2020 | 894 | 0.120 |
Why?
|
| Severity of Illness Index | 7 | 2025 | 3072 | 0.120 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2019 | 705 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 684 | 0.120 |
Why?
|
| Comorbidity | 4 | 2020 | 1614 | 0.120 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 158 | 0.120 |
Why?
|
| Recurrence | 4 | 2022 | 1471 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2017 | 1411 | 0.110 |
Why?
|
| Weight Loss | 1 | 1998 | 516 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 388 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 399 | 0.110 |
Why?
|
| Registries | 5 | 2021 | 1563 | 0.110 |
Why?
|
| Echocardiography, Doppler | 2 | 2007 | 173 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2019 | 3226 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 560 | 0.110 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2014 | 47 | 0.110 |
Why?
|
| Heart | 3 | 2023 | 749 | 0.110 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 7204 | 0.110 |
Why?
|
| Medical Staff | 1 | 2013 | 7 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2013 | 20 | 0.110 |
Why?
|
| Catheter Ablation | 1 | 2016 | 245 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2016 | 278 | 0.110 |
Why?
|
| Leukemia, Myeloid | 1 | 2014 | 82 | 0.110 |
Why?
|
| Nurse's Role | 1 | 2013 | 40 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 771 | 0.100 |
Why?
|
| Nurses | 1 | 2013 | 75 | 0.100 |
Why?
|
| Pharmacists | 1 | 2013 | 99 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 134 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1977 | 0.100 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2004 | 64 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2015 | 309 | 0.100 |
Why?
|
| Odds Ratio | 2 | 2016 | 1337 | 0.100 |
Why?
|
| Emergencies | 1 | 2013 | 185 | 0.090 |
Why?
|
| Tachycardia, Ventricular | 1 | 2014 | 207 | 0.090 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 229 | 0.090 |
Why?
|
| Survival Rate | 5 | 2020 | 2207 | 0.090 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 1999 | 787 | 0.090 |
Why?
|
| Transportation of Patients | 1 | 2011 | 54 | 0.090 |
Why?
|
| Time | 1 | 2011 | 100 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 1093 | 0.090 |
Why?
|
| Aspirin | 3 | 2018 | 231 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2013 | 310 | 0.090 |
Why?
|
| Confidence Intervals | 1 | 2011 | 300 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 181 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 137 | 0.080 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2009 | 38 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2022 | 225 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 1153 | 0.080 |
Why?
|
| Combined Modality Therapy | 3 | 2008 | 1315 | 0.080 |
Why?
|
| Heart Arrest | 1 | 2014 | 376 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 756 | 0.080 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2009 | 87 | 0.080 |
Why?
|
| Calcinosis | 2 | 2001 | 194 | 0.080 |
Why?
|
| Logistic Models | 2 | 2016 | 1909 | 0.070 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 1197 | 0.070 |
Why?
|
| Fibrinolysis | 1 | 2008 | 42 | 0.070 |
Why?
|
| Vascular Patency | 1 | 2008 | 196 | 0.070 |
Why?
|
| Retrospective Studies | 9 | 2021 | 17481 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 2083 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2009 | 409 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 522 | 0.060 |
Why?
|
| Mortality | 2 | 2019 | 262 | 0.060 |
Why?
|
| Blood Flow Velocity | 2 | 2009 | 467 | 0.060 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5505 | 0.060 |
Why?
|
| Vasodilator Agents | 2 | 2004 | 213 | 0.060 |
Why?
|
| Hospitalization | 3 | 2020 | 1887 | 0.060 |
Why?
|
| Equipment Safety | 2 | 2002 | 37 | 0.060 |
Why?
|
| Incidence | 3 | 2025 | 3393 | 0.060 |
Why?
|
| Adult | 6 | 2018 | 31946 | 0.060 |
Why?
|
| Heparin | 2 | 2007 | 226 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 3027 | 0.060 |
Why?
|
| Nitroprusside | 1 | 2004 | 42 | 0.060 |
Why?
|
| Clinical Protocols | 2 | 2018 | 244 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 678 | 0.050 |
Why?
|
| Brachytherapy | 1 | 2004 | 92 | 0.050 |
Why?
|
| Wounds, Penetrating | 1 | 2004 | 141 | 0.050 |
Why?
|
| Adenosine | 1 | 2004 | 139 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2003 | 135 | 0.050 |
Why?
|
| Europe | 2 | 2014 | 384 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 240 | 0.050 |
Why?
|
| Coma | 1 | 2021 | 57 | 0.050 |
Why?
|
| Mammary Arteries | 1 | 2001 | 30 | 0.050 |
Why?
|
| Ticlopidine | 1 | 2001 | 30 | 0.040 |
Why?
|
| Coronary Aneurysm | 1 | 2001 | 33 | 0.040 |
Why?
|
| Thrombin | 1 | 2001 | 62 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2001 | 117 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2021 | 137 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2013 | 1735 | 0.040 |
Why?
|
| Atherectomy | 1 | 2020 | 12 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 2977 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 103 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2020 | 53 | 0.040 |
Why?
|
| Aneurysm, False | 1 | 2001 | 94 | 0.040 |
Why?
|
| Prognosis | 5 | 2016 | 5074 | 0.040 |
Why?
|
| Cause of Death | 2 | 2016 | 502 | 0.040 |
Why?
|
| Specialty Boards | 1 | 2019 | 19 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 226 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2021 | 799 | 0.040 |
Why?
|
| Vascular Calcification | 1 | 2020 | 67 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 3849 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 105 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 82 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 360 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2020 | 184 | 0.040 |
Why?
|
| Equipment Design | 2 | 2016 | 613 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 2295 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2019 | 1240 | 0.040 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 1999 | 88 | 0.040 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 1999 | 79 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 3689 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 1999 | 134 | 0.040 |
Why?
|
| Thrombosis | 1 | 2003 | 537 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2020 | 268 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 406 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 455 | 0.030 |
Why?
|
| Critical Illness | 1 | 2021 | 626 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2016 | 22 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2019 | 338 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 560 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 875 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 309 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 237 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 75 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2001 | 2196 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 314 | 0.030 |
Why?
|
| Ascites | 1 | 2016 | 99 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2019 | 413 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 739 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1384 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 148 | 0.030 |
Why?
|
| Edema | 1 | 2016 | 142 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 825 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 74 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2018 | 522 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 777 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2014 | 6664 | 0.030 |
Why?
|
| Stroke Volume | 1 | 2016 | 530 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1383 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2009 | 1667 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 343 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2006 | 971 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 734 | 0.020 |
Why?
|
| Population Density | 1 | 2011 | 35 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2016 | 598 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2004 | 830 | 0.020 |
Why?
|
| North America | 1 | 2011 | 260 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3423 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 5173 | 0.020 |
Why?
|
| Program Development | 1 | 2011 | 190 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2011 | 293 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2002 | 363 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2006 | 1253 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 292 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2009 | 226 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 79 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 570 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2009 | 243 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 934 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 107 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 816 | 0.010 |
Why?
|
| Protamines | 1 | 2004 | 13 | 0.010 |
Why?
|
| Constriction | 1 | 2004 | 50 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 454 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 1165 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 2003 | 22 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 604 | 0.010 |
Why?
|
| Acute Disease | 1 | 2006 | 1189 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1485 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2003 | 87 | 0.010 |
Why?
|
| Minnesota | 1 | 2002 | 181 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 251 | 0.010 |
Why?
|
| Microcirculation | 1 | 2003 | 118 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 831 | 0.010 |
Why?
|
| Drug Monitoring | 1 | 2003 | 181 | 0.010 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2001 | 42 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2002 | 333 | 0.010 |
Why?
|
| Heart Atria | 1 | 2003 | 333 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 8 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1999 | 25 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2001 | 158 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 171 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 1999 | 166 | 0.010 |
Why?
|
| Exercise Test | 1 | 1999 | 267 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2006 | 1150 | 0.010 |
Why?
|
| Foreign Bodies | 1 | 1999 | 109 | 0.010 |
Why?
|
| Prostheses and Implants | 1 | 1999 | 164 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2001 | 1596 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 722 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 3640 | 0.010 |
Why?
|